Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.

Medical device maker Abbott recalled two glucose monitors that were giving users an incorrect low glucose reading. Over an ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the ...

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...

Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least ...